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Mesothelioma
W. Weder*
Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
Malignant pleural mesothelioma continues to be a clinical
challenge. The disease is associated with asbestos exposure; its
incidence will continue to increase in regions even though the
commercial use of asbestos has been banned, and is certain to
continue to contribute to cancer mortality in regions of the
word lacking worker protection and persisting with its
commercial use. It will depend on political actions and the will
of governments to change this situation [1]. Once diagnosed
with pleural mesothelioma, patients nearly invariably die of the
disease. Advances have been made in the immunohistochemical
diagnosis of the disease allowing a firm diagnosis in most
patients. While some benefit of chemotherapy for advanced
disease has been established, many other aspects of treatment
continue to be controversial, in particular in regard to surgery
and radiotherapy. However, the best survival data are reported
from groups using multimodality treatment including neo- or
adjuvant chemotherapy and extrapleural pneumonectomy
(EPP). Over the past few years several review articles have dealt
with pleural mesothelioma [2–5] and recently the new
European Respiratory Society/European Society of Thoracic
Surgeons guidelines have been published [6].
epidemiology
In Europe, where commercial use of asbestos has been banned
for many years, a first analysis predicted that male
mesothelioma deaths will to continue to increase and peak in
the year 2020 [7]. More recent models indicate that the increase
may already be levelling off and the peak should occur earlier at
around 2015 [8, 9]. These estimates have taken into
consideration a certain latency period and the ban on
commercial asbestos exposure in the early 1990s. However,
recent data from the Italian Mesothelioma Registry
demonstrated an even longer median latency than expected.
The median latency was 44.6 years and increasing over time in
a linear fashion [10]. Environmental asbestos exposure is
common in some villages in Turkey. Here the rate of
mesothelioma mortality can be >100-fold higher than in
control villages [11].
molecular pathology
Although mesothelioma development is linked to asbestos
fibers such as crocidolite, amosite and tremolite, the exact
mechanism of mesothelioma development is unclear. The
pleura is the target for the carcinogenic activity of asbestos
probably because asbestos can translocate from the lung to the
pleural space and then concentrate in the parietal pleura at the
sites of lymphatic drainage [12].
To get insight on genes relevant to pathology, chromosomal
aberrations have been investigated. Cytogenetic studies have
revealed highly complex karyotypic changes involving all
chromosomes with chromosomal losses more frequent than
chromosomal gain [13]. A number of recurrent abnormalities
have been found, among those deletion of 9p21 and 22q12. The
single most consistent numerical chromosomal change
concerns chromosome 22. The tumor suppressor merlin is
encoded by the neurofibromatosis type 2 gene (NF2), which is
located on chromosome 22q12, and mutations in this gene have
been found in 40% of mesotheliomas [14–16]. Re-expression of
NF2 inhibits invasiveness of mesothelioma cells [17].
Mesotheliomas develop at higher frequency in mice with only
one NF2 allele compared with the wild type when
experimentally exposed to asbestos fibers [18]. In addition, in
asbestos-induced tumors the remaining NF2 allele is lost,
indicating that the NF2 gene has a key role as ‘gatekeeper’ in
asbestos-induced mesothelioma [18]. Additional
characterization of this model led to the discovery that loss of
the remaining allele was accompanied by loss of INK4a/ARF
[19]. The INK4a/ARF locus is located at the 9p21 region and
encodes two distinct proteins translated from alternatively
spliced mRNA: p16 and ARF. p16 inhibits cyclin-dependent
kinase-4/6, thereby controlling retinoblastoma
phosphorylation, hence cell cycle arrest in G1. ARF promotes
MDM2 degradation preventing MDM2-mediated degradation
of p53. Mesotheliomas lack expression of both p16 and ARF
proteins [20, 21] due to gene deletion [22–24] or methylation
[25–27]. In experimental animal models, targeted inactivation
of NF2 by adeno-Cre infection of the mesothelial cells lining
the thoracic cavity rarely results in mesothelioma. However,
concomitant loss of INK4a/ARF strongly accelerates
mesothelioma development [28], indicating that functional
inactivation of NF2 leads to tumor development in
a ‘permissive’ (INK4a/ARF deficient) background. If this
animal model is representative of key pathways for
mesothelioma development in humans, one may ask the
question why mutations in this gene have been found ‘only’ in
40% of mesothelioma [14–16]. One of the reasons could be that
NF2 might be inactivated by other ways than deletion.
The human NF2 gene consists of 17 exons and spans 95 kb
of DNA. NF2 transcripts undergo alternative splicing,
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generating multiple isoforms [29]. Isoform I, missing exon 16,
and isoform II, containing all 17 exons, are the two
predominant species. As the result of alternative splicing,
isoform I encodes a 595-amino-acid protein. Isoform II differs
from isoform I only at the C terminus. Insertion of exon 16
into the mRNA provides a new stop codon, resulting in a 590-
amino-acid protein that is identical to isoform I over the first
579 residues. Other less abundant variants such as delE2,
missing exon 2, delE3, missing exon 3, and delE2/3, missing
exons 2 and 3, have been described [29–32]. Only isoform I
functions as a tumor suppressor and this activity is
phosphorylation dependent [33, 34]. Phosphorylation of
Ser518 by PKA or PAK inactivates merlin by disrupting the
intramolecular self-association. Myosin phosphatase MYPT1-
PP1d dephosphorylates Ser518 and thereby activates merlin.
PP1d docks on merlin through binding of its targeting subunit,
MYPT1 and a missense mutation (L339F) found in brain
tumors ablates its binding to MYPT1, indicating that
disruption of NF2 function indeed happens also by avoiding
dephosphorylation [35]. This is further supported by the
observation that protein kinase C-potentiated phosphatase
inhibitor of 17 kDa (CPI-17), a cellular inhibitor of MYPT1,
induces neoplastic transformation in vitro by inactivating NF2/
merlin [36].
No data are available yet on NF2 isoforms expressed in
mesothelioma and their phosphorylation status, but the recent
findings of NF2/merlin inactivation in DU145 prostate cancer
cells by PAK-mediated constitutive phosphorylation [37]
indicate that this possibility might have clinical relevance.
Phosphorylation of residues other than Ser518 inhibits NF2/
merlin function in a different way. Indeed, Akt-driven
phosphorylation on Thr230 and Ser515 leads to NF2/merlin
ubiquitination and degradation [38]. This indicates that in
tumors expressing an intact NF2/merlin, an active PI3K
pathway would also result in NF2 functional inactivation.
Malignant mesothelioma tumor specimens demonstrate high
levels of phosphorylated Akt expression [39] and this may be
linked to overexpression of autocrine growth factors such as
hepatocyte growth factor and its receptor c-Met [39, 40].
Activated PI3K generates a lipid second messenger, which is
essential for translocation of Akt to the plasma membrane,
where it is phosphorylated and activated by phosphoinositide-
dependent kinase 1. Phosphorylated Akt then conveys
downstream signals, promoting cellular proliferation and
survival over apoptosis. Activity of the PI3K/Akt pathway is
negatively regulated by the phosphatase and tensin analogue
(PTEN) tumor suppressor gene, and overexpression of PTEN
in mesothelioma cells induced hypophosphorylation of Akt and
apoptosis [41]. In addition poor survival of malignant pleural
mesothelioma patients lacking PTEN expression has been
observed [42].
If inactivation of NF2 in an INK4a/ARF-deficient
background triggers the development of malignant
mesothelioma one could ask how and why these genes could act
as ‘gatekeeper’ and ‘caretaker’. The answers to these questions
can be inferred from the fact that NF2/merlin is required for
the assembly but not the maintenance of apico-lateral
junctional complexes [43], which means that NF2 loss will be
mostly important when it occurs in dividing cells, e.g. during
tissue repair. This might be one of the reasons why it is
disrupted in mesothelioma, which is thought to result from
chronic mesothelium injury by asbestos fibers [44]. Cells that
cannot form apico-lateral junctional complexes will be unable
to form a well-organized tissue and will be resistant to contact-
dependent growth arrest. Chronic injury stimulates tissue
repair by activating stem cells [45] and mesothelioma
carcinogenesis could proceed by misappropriating homeostatic
mechanisms that govern tissue repair and stem cell self-
renewal. This concept is supported by the observation that the
Wnt-dependent stem cell signaling pathway is dysregulated in
mesothelioma. Indeed, there is a significant transcriptional
downregulation of the secreted frizzled-related proteins (sFRPs)
in malignant pleural mesothelioma primary tissues and cell
lines [46]. sFRPs, a family of five secreted glycoproteins, have
been identified as possible dominant-negative modulators of
the Wnt signal transduction pathway. Transfection of the SFRP
gene construct into MPM cell lines lacking sFRP expression
resulted in apoptosis and growth suppression [46].
The idea of mesothelioma as one of the chronic
inflammation-related cancers is reinforced by the recent
observation that inflammation-associated transcription factor
NF-jB is constitutively active in various mesothelioma cell lines
[47]. This results in activation of anti-apoptotic mechanisms as
frequently observed in mesothelioma [48].
As mentioned in the Diagnosis section below, during
mesothelioma development epithelial cells undergo epithelial to
mesenchymal transition and another gene, p15, also located in
the 9p21 locus, seems to be involved. Indeed on the one hand,
p15 is often silenced by methylation in mesothelioma [27] and
on the other hand, in an experimental animal model, combined
deficiency of p16 and p15 results in a different type of soft
tissue sarcoma composed of mixed cell types and showing
biphasic differentiation [49].
diagnosis
Morphologically, pleural mesothelioma presents most often as
epithelioid and less commonly as mixed disease or especially as
a pure sarcomatoid form. Even less common is the well-
differentiated papillary mesothelioma of the pleura. This
disease was initially described in the peritoneum of young
women without a history of asbestos exposure. A case series
from France described the pleural variant of this disease, which
is characterized by lack of deep invasion and association with
a more indolent course; however, in some cases with evaluation
to pleural mesothelioma. It occurs equally in men and women
and a history of asbestos exposure has been identified in half of
the cases [50].
The morphological diagnosis of pleural mesothelioma is
generally made by a pleural biopsy, preferentially by
thoracoscopy. Immunohistochemical staining has a central role
in the diagnostic process. Markers indicative of the diagnosis of
mesothelioma are calretinin, D2-40, WT1, cytokeratin 5/6 and
podoplanin, while epithelial membrane antigen (EMA),
carcino-embryonic antigen (CEA) and thyroid transcription
factor 1 (TTF1-1) are indicative of the diagnosis of
adenocarcinoma, the latter in particular of adenocarcinoma of
lung origin [51–53]. In contrast to these markers, staining for
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mesothelin is less useful for the diagnosis of mesothelioma [54].
The distinction between sarcomatous mesothelioma and true
sarcoma or the rare sarcomatoid carcinoma of the lung can also
be a challenge. Here, a recent publication recommended the use
of cytokeratin antibodies together with WT1 [55].
The identification of mesothelin-related proteins as serum
markers of mesothelioma has raised great hopes of their
potential to monitor the disease under therapy and their
investigation for the screening of individuals exposed to
asbestos [56]. Since, several investigators have examined the
potential clinical role of mesothelin. Mesothelin serum levels
were found to be elevated in patients with mesothelioma and
ovarian cancer [57]. Serum levels were higher in patients with
mesothelioma than in patients with lung cancer and in one
study differed significantly between stage I and higher stages of
mesothelioma [58, 59]. The discriminating power to
distinguish between non-small-cell lung cancer and
mesothelioma was increased by combining serum CEA and
mesothelin measurements [60].
surgery
The role of surgery in pleural mesothelioma continues to be
a matter of debate. The procedures used for the treatment of
mesothelioma are thoracoscopy and pleurodesis for diagnosis
and pleural effusion control, pleurectomy with tumor
decortication of the lungs for debulking and major
cytoreduction and especially EPP as the most radical resection.
A systematic review based on the literature from 1985 to 2004
could not determine whether the use of EPP improves survival
or effectively palliates symptoms of pleural mesothelioma [61].
Some centers advise pleurectomy and decortication for patients
with compromised cardiac or pulmonary function, advanced
age or certain disease distributions, in particular with early
disease, in order to remove the bulk of the tumor while sparing
lung function. When comparing their results with EPP with
video-assisted thoracoscopic pleurectomy and decortication in
patients >65 years of age, the group in Leicester (UK)
documented a reduced 30-day mortality with the VATS
procedure with a similar survival outcome (11.5 months for
EPP and 14 months for pleurectomy and decortication) [62]. In
some series the outcome after EPP was worse in patients with
N2 disease [63, 64] as investigated in a case–control study
comparing the outcome in patients with N2 disease between
EPP and open radical pleurectomy and decortication. The two
groups did not differ in stage, but differed in age with older
patients undergoing pleurectomy and decortication. With 15
and 16 months, there was no difference in survival [65].
Combing the experience of three large centers in the United
States, the outcome of 663 patients treated between 1990 and
2006 was analyzed retrospectively [66]. The median survival for
the entire group was 14 months with a small advantage for
pleurectomy and decortication. Operative mortality was 7% for
EPP and 4% for pleurectomy and decortication. A multivariate
analysis demonstrated a hazard ratio for EPP of 1.4. A
difference was noted in the site of first recurrence. Local
recurrence occurred in 33% versus 65%, distant recurrence in
66% versus 35% in patients undergoing EPP versus
pleurectomy and decortication. However, because of biases in
patient selection for a certain procedure and the retrospective
nature of the analysis, no firm conclusions can be made until
the question is addressed in a controlled prospective trial.
multimodality therapy including
neoadjuvant chemotherapy and EPP
The largest published experience with EPP in conjunction with
adjuvant chemotherapy and radiotherapy was published from
the Boston group. An update from this group included 183
patients intended for the trimodality approach [63]. Median
survival in the 176 patients alive after surgery was 19 months.
The availability of more effective chemotherapy regimens and
the experience of neoadjuvant chemotherapy in stage IIIA
non-small-cell lung cancer prompted us to explore the role of
neoadjuvant chemotherapy and EPP in pleural mesothelioma.
In a pilot study on 19 patients treated at the University Hospital
of Zu¨rich, the response to neoadjuvant cisplatin and
gemcitabine was 31%, and 16 patients underwent EPP with no
perioperative mortality. The median survival of all patients was
23 months, and two of these patients remained disease free for
6 years after surgery [67]. These results were confirmed in
a prospective multicenter phase II trial in Switzerland. Sixty-
one patients with T1–localized T3 and N01–N2 disease and
including all histologies received three cycles of neoadjuvant
cisplatin and gemcitabine [68]. Extrapleural pneumonectomy
was performed in 45 (74%) and complete resection was felt to
be achieved in 37 (61%) patients. Operative mortality was
2.2%. The median survival by intent to treat was 19.8 months,
the median survival for patients undergoing EPP was 23
months. Quality of life measurements were performed.
Psychological distress showed only minor variation over time
with distress above the cut-off score indicating no morbidity in
82% at baseline and 76% at 3 months after surgery. These
results compare favourably with the series from Boston with
a median survival after EPP of 19 months [69], a series from the
Mayo Clinic with a median survival after EPP of 12 months
[70] and a series from the MD Anderson Cancer Center with
a median survival after EPP and intensity-modulated
radiotherapy of 10.2 months [71].
Based on the results of a landmark trial [72] demonstrating
the survival benefit of a combination chemotherapy of cisplatin
with pemetrexed over cisplatin alone this combination has been
adopted for a neoadjuvant approach by most centers. While the
published results and reviews [73] so far are indicative that
radical surgery may indeed be associated with longer survival
than chemotherapy alone, final proof of this concept will only
come from a randomized study. These data will hopefully be
forthcoming from the MARS (mesothelioma and radical
surgery) trial initiated in the UK.
While the rate of operative mortality after EPP is now <5% in
experienced centers, EPP is associated with significant operative
morbidity requiring the attention of a dedicated team. Three
recent series have analyzed their operative complications. The
group in Boston reported minor and major complications in
60% of patients operated on and overall mortality was 3.4%
[74]. The group from Leicester reported significant morbidity
in 63% and an overall mortality of 6.7% [75]. Risk factors for
perioperative morbidity were induction chemotherapy for
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acute lung injury and symptomatic mediastinal shift, right-
sided procedures and prolonged operations for technical
complications such as dehiscence of the diaphragmatic patch,
chylothorax or fistulae. Our group in Zu¨rich reported
postoperative complications in 62% and mortality in 3.1%
[76]. Most frequent complications included postoperative
empyema in 16%, bronchopulmonary fistula in 10%,
chylothorax in 8% and patch failure in 6%. All could be
successfully managed.
radiotherapy
Radiotherapy can be effective for local palliation and has been
suggested to be of benefit for the prevention of malignant
seeding after invasive procedures [77, 78]; however, this has
recently been thrown into doubt by other reports and is no
longer recommended [79, 80].
After EPP most patients have tumor recurrence in the
ipsilateral chest. The rate of local relapse reported from the
Boston group was 35.% [81]. A phase II trial from the
Memorial Sloan-Kettering Cancer Center indicated a reduced
rate (6%) of local failure after EPP with high-dose
postoperative radiotherapy [82]. This was confirmed in a study
of intensity-modulated radiation therapy from the MD
Anderson Cancer Center, demonstrating local failure in 13%
with distant failure of 54% [71]. Intensity-modulated
radiotherapy after extrapleural pneumotectomy can be
associated with severe or lethal pulmonary toxicity. A series of
13 patients treated in Boston reported the development of fatal
pneumonitis in six patients, the most likely explanation being
dose–volume effects on the contralateral lung [83]. The author
suggested specific metric techniques to avoid this toxicity [84].
The rate of lethal pulmonary toxicity was much lower in
patients of the MD Anderson Cancer Center series where in
a retrospective analysis the importance of low V20 was
emphazised [85]. The impact of high-dose hemithoracic
radiation on toxicity and local failure after neoadjuvant
chemotherapy and extrapleural pneumonecty is the subject of
an ongoing prospective randomized study of the Swiss Group
for Clinical Cancer Research.
imaging
The role of imaging in pleural mesothelioma has been
examined in two recent reviews [86, 87]. The role of 2-
[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission
tomography (FDG-PET) and PET–CT for staging and selection
of patients for surgery has been investigated in smaller series. A
first report on PET demonstrated increased uptake of pleural
mesothelioma in 62 of 63 patients and identification of six
patients with N3 or M1 disease subsequently confirmed by
other means. However, the sensitivity of PET in identifying the
21 patients with surgical T4 status was only 19% and the nine
patients with surgical N2 only 11% [88]. Using integrated PET–
CT for the staging of potentially resectable pleural
mesothelioma, extrathoracic disease that was not identified by
conventional staging was found in 7 of 29 patients, but tumor
stage was correctly identified in only 15 of 24 and nodal stage
only in 6 of 17 [89]. Thus, based on these studies, the major
role of PET and PET–CT lies in the identification of
extrathoracic disease and not in the determination of T and N
stage. FDG-PET cannot be used for assessment of local disease
in patients who underwent talc pleurodesis, since this
procedure can lead to persistant pleural FDG uptake [90].
Response assessment in malignant mesothelioma remains
difficult; however, the adoption of modified RECIST criteria by
most investigators has improved the situation somewhat. They
were developed because of the nature of pleural mesothelioma
to grow as a rind and are reported as the difference in the sum
of two measurements perpendicular to the chest wall at three
different levels. Response according to these criteria predicted
for survival and forced vital capacity [91]. While modified
RECIST is the standard currently used in assessing response in
pleural mesothelioma, more sophisticated methods such as
computerized analysis of CT scans [92] and total glycolytic
volume determined in PET–CT have been developed and await
clinical validation. FDG-PET might have a role in the
assessment of tumor response. A study on a group of 22
patients reported an association of early metabolic response
with time to progression, while no such association was found
using CT-based criteria [93]. A second study on 23 patients
found an association of an early reduction in the total glycolytic
volume with survival [94].
systemic chemotherapy
The palliative effect of combination chemotherapy for patients
with pleural mesothelioma has been documented in a study
from the UK. An update of the experience from the Royal
Marsden Hospital focused on the palliative benefits of
mitomycin C, vinblastine and cisplatin. While the rate of
objective response was only 13.5% and the median survival
only 7 months, 69% of patients reported an improvement of
symptoms. The symptoms best responding to treatment were
pain in 71%, cough in 62% and dyspnoea in 50% [95].
Two large randomized trials have proved the benefit of the
addition of a folate antagonist to cisplatin. A large prospective
trial including 456 patients comparing cisplatin alone with
cisplatin and pemetrexed demonstrated a significantly better
response (17% versus 41%) and median survival (9.3 months
versus 12.1 months) with the cisplatin–pemetrexed
combination over cisplatin alone [72]. A post-study analysis on
the use of second-line chemotherapy supports the assumption
that this survival effect is not the result of second-line
chemotherapy [96]. The EORTC study, which included 250
patients to examine the addition of raltitrexed to cisplatin, also
proved superioritiy of the combination chemotherapy for
response (14% versus 24%) and median survival (8.8 months
versus 11.1 months) [97]. Based on the registration of
pemetrexed and the trial results, the combination of cisplatin
and pemetrexed has since become the preferred chemotherapy
regimen for patients with pleural mesothelioma.
Pemetrexed in combination with carboplatin has been
explored in two large phase II studies. They reported response
rates of 19% and 21% and median survival of 12.7 and 14
months. Non-hematological toxicity was negligible and febrile
neutropenia occurred in only one study at a rate of 1% of
patients [98, 99]. Based on the activity of both agents in
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mesothelioma, the combination of pemetrexed and
gemcitabine has been investigated in a phase II study. The
authors concluded that the efficacy was not better than
expected with pemetrexed alone and inferior to the platin–
pemetrexed combinations [100].
The effect of early or delayed chemotherapy in
symptomatically stable patients was explored in a small
randomized trial also using mitomycin C, vinblastine and
cisplatin chemotherapy [101]. Twenty were in the early
chemotherapy group and 22 in the delayed chemotherapy
group, of which 17 eventually received chemotherapy. The
median time to symptomatic progression was significantly
better in the early chemotherapy group as compared with the
late chemotherapy group with 25 weeks as compared with 11
weeks. There was a trend to better survival in the early
chemotherapy group with 14 as compared with 10 months.
The role of second-line chemotherapy in pleural
mesothelioma needs to be defined. Pemetrexed alone or in
combination with carboplatin has yielded objective responses
of 20% in a small series of patients with disease progression
after cisplatin chemotherapy [102]. Recently a prospective
randomized phase III study enrolling 243 patients examined the
role of pemetrexed versus best supportive care [103]. This study
demonstrated a better disease control rate for the pemetrexed
arm (59% versus 19%); however, there was no significant
survival benefit. The survival results might have been
influenced by post-discontinuation chemotherapy, which was
given to 28% of patients in the pemetrexed group and 51% of
patients in the best supportive care group. The question of how
to treat patients with progression after cisplatin and
pemetrexed is unanswered. Vinorelbine has demonstrated
activity when used in first-line therapy and might be
a reasonable choice [104]. Vinflunine, a new microtubule
inhibitor, has recently been demonstrated to have clinical
activity when used in first line [105].
new approaches
Despite the expression of epidermal growth factor receptor in
pleural mesothelioma and promising preclinical data, single-
agent gefitinib and erlotinib were found to have no significant
clinical activity [106, 107]. Because platelet-derived growth
factor was thought to be an important factor in the
pathogenesis of mesothelioma and c-kit expression was
reported to be present in one-third of mesotheliomas in one
small series, the activity of single-agent imatinib has been
examined in two phase II studies. No objective responses were
seen [108, 109]. In contrast, clinical signals with objective
responses were reported in abstract form with multitargeted
tyrosine kinase inhibitors vatalanib and sorafenib, both
including vascular endothelial growth factor (VEGF)-2 as target
[110, 111], prompting further clinical studies with this group of
agents.
The potential role of the anti-VEGF antibody bevacizumab in
mesothelioma has been explored in a large randomized phase II
study in combination with cisplatin and gemcitabine. The
result has been presented and failed to show a survival benefit
for bevacizumab in this combination [112]. A first report on
the potential of thalidomide demonstrated disease stabilization
in 27% of 40 patients [113], a firm conclusion, however, can
only be drawn after the completion of a prospective phase III
trial on thalidomide maintenance that is currently being
conducted in the Netherlands.
Preclinical studies with the proteosome inhibitor bortezomib
have demonstrated activity and synergy with cisplatin in
mesothelioma cell lines and clinical phase II studies with this
agent in pleural mesothelioma have been initiated [114].
Histone deacetylase inhibitors are also under investigation.
In a phase I study with the suberoylanilide hydroxamic acid in
advanced cancer unconfirmed responses have been reported
in 3 of 13 patients with mesothelioma, prompting further
investigations into this disease in a prospective randomized
phase III study in second line [115]. As reviewed by Fenell [5]
other histone deacetylase inhibitors being explored in early
clinical trials in mesothelioma are belonistat [116] and
desipeptide in combination with flavopiridol, the latter
combination having demonstrated cytotoxicity in
mesothelioma cells [116]. The potential dependence of
mesothelioma cells on external arginine because of loss of
expression of argininosuccinate has led to the investigation of
a pegylated form of arginine deiminase [117, 118].
Mesothelin might not only serve as diagnostic marker in
serum or tissue, but also represent a target for therapy of
mesothelioma [119]. Patients with mesothelioma and other
tumors expressing mesothelin have been treated in a phase I
study with a recombinant anti-mesothelin immunotoxin.
Despite transient pleuritis as dose-limiting toxicity,
treatment was otherwise well tolerated and clinical activity has
been observed [120]. A chimeric anti-mesothelin antibody
has been developed, which is now undergoing clinical
testing [121].
Other targeted strategies have been elucidated in preclinical
studies that might lead to new therapeutic approaches. These
include targeting the apoptotic pathway with antisense
oligonucleotides to survivin or inducing apoptosis with the
TRAIL antibodies mapatumumab or lexatumumab, both
approaches enhancing the effect of cisplatin on mesothelioma
cells [122, 123]. Inhibition of the met receptor with tyrosine
kinase inhibitors and inhibition of activated c-src by desatinib
both decreased the growth of mesothelioma cell lines [124,
125]. A humanized antibody to CD26 has been shown to
induce antibody-dependent cellular cytotoxicity against
mesothelioma cell lines and to inhibit mesothelioma cell
growth in a xenograft system [126].
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